Ibuprofen · oral tablet
NSAID
Approved uses
Rheumatoid arthritis and osteoarthritis, including flare-ups of chronic disease
1200 mg to 3200 mg daily, as 400 mg, 600 mg or 800 mg three or four times a day, and never more than 3200 mg in total a day. Patients with rheumatoid arthritis seem to require higher doses than patients with osteoarthritis. In well-controlled trials, patients on 3200 mg did not show a better mean response than patients on 2400 mg
A response is sometimes seen in a few days to a week, but most often by two weeks
Mild to moderate pain and primary dysmenorrhea
400 mg every 4 to 6 hours as needed for mild to moderate pain; for primary dysmenorrhea, 400 mg every 4 hours as needed, starting at the earliest onset of that pain
In controlled analgesic trials, doses above 400 mg were no more effective than 400 mg
OFF-LABELNot in the FDA label for this product
Episcleritis
200 to 600 mg by mouth three or four times a day, given with food or antacids, for at least 10 to 14 days, as an alternate steroid-sparing initial therapy (The Wills Eye Manual). Kanski's Clinical Ophthalmology gives 200 mg three times a day for the occasional case that needs an oral NSAID. This label's tablets come only in 400, 600 and 800 mg strengths
Textbook · no ibuprofen RCT
No randomized trial of oral ibuprofen in episcleritis appears in PubMed, so this regimen rests on textbook and guideline recommendation, and those sources split on where oral NSAIDs belong. The Wills Eye Manual lists them as an alternate steroid-sparing initial therapy and notes that many physicians prefer them to topical NSAIDs or steroids as initial therapy. A 2022 Royal Victoria Eye and Ear Hospital guideline names an oral NSAID, with or without a topical steroid, as first-line. Kanski's Clinical Ophthalmology says an oral NSAID is occasionally required, and Ophthalmology (2023) reserves systemic NSAIDs for severe or recurrent episcleritis.
Contraindications
- Known hypersensitivity to ibuprofen
- Asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, as severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients
- In the setting of coronary artery bypass graft (CABG) surgery
400 mg (bottles of 30, 60, 90, 100 and 500), 600 mg and 800 mg (bottles of 30, 50, 60, 90, 100 and 500)
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that possesses analgesic and antipyretic activities. Its mode of action, like that of other NSAIDs, is not completely understood, but may be related to prostaglandin synthetase inhibition.
Warnings & Precautions
- Ophthalmological effects: Blurred or diminished vision, scotomata, and changes in color vision have been reported. If a patient develops such complaints, ibuprofen should be discontinued and the patient should have an ophthalmologic examination that includes central visual fields and color vision testing.
- Cardiovascular thrombotic events: NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Ibuprofen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. Avoid use in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events.
- Gastrointestinal bleeding, ulceration, and perforation: NSAIDs cause an increased risk of serious gastrointestinal bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time, without warning symptoms. Elderly patients are at greater risk, and patients with a prior history of peptic ulcer disease or GI bleeding have a greater than 10-fold increased risk for a GI bleed. Discontinue the NSAID until a serious GI adverse event is ruled out.
- Hypertension: NSAIDs, including ibuprofen, can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies. Blood pressure should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
- Heart failure and edema: A meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for heart failure in COX-2 selective-treated and nonselective NSAID-treated patients compared to placebo, and fluid retention and edema have been observed in some patients treated with NSAIDs. Avoid use in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.
- Renal effects: Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Where renal prostaglandins have a compensatory role in the maintenance of renal perfusion, an NSAID may cause a dose-dependent reduction in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk are those with impaired renal function, heart failure or liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly.
- Advanced renal disease: No information is available from controlled clinical studies in patients with advanced renal disease, so treatment with ibuprofen is not recommended in these patients.
- Anaphylactoid reactions: As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ibuprofen. Ibuprofen should not be given to patients with the aspirin triad. Emergency help should be sought in cases where an anaphylactoid reaction occurs.
- Preexisting asthma: Since cross reactivity, including bronchospasm, between aspirin and NSAIDs has been reported in aspirin-sensitive patients, ibuprofen should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
- Serious skin reactions: NSAIDs, including ibuprofen, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal, and can also cause fixed drug eruption (FDE). These serious events may occur without warning. Discontinue ibuprofen at the first appearance of skin rash or any other sign of hypersensitivity. Ibuprofen is contraindicated in patients with previous serious skin reactions to NSAIDs.
- Drug reaction with eosinophilia and systemic symptoms (DRESS): DRESS has been reported in patients taking NSAIDs such as ibuprofen, and some of these events have been fatal or life-threatening. Early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ibuprofen and evaluate the patient immediately.
- Fetal toxicity: Avoid use of NSAIDs, including ibuprofen, in pregnant women at about 30 weeks gestation and later, when they increase the risk of premature closure of the fetal ductus arteriosus.
- Oligohydramnios and neonatal renal impairment: Use of NSAIDs at about 20 weeks gestation or later may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit use to the lowest effective dose and shortest duration possible, consider ultrasound monitoring of amniotic fluid if treatment extends beyond 48 hours, and discontinue ibuprofen if oligohydramnios occurs.
- Hepatic effects: Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST, three or more times the upper limit of normal, in approximately 1%. Rare severe hepatic reactions, including jaundice, fulminant hepatitis, liver necrosis, and hepatic failure, have been reported, some of them fatal. Discontinue ibuprofen if signs of liver disease develop or systemic manifestations such as eosinophilia or rash occur.
- Hematological effects: Anemia is sometimes seen in patients receiving NSAIDs, so patients on long-term treatment should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and prolong bleeding time in some patients, though their effect on platelet function is less than that of aspirin, of shorter duration, and reversible, so patients with coagulation disorders or receiving anticoagulants should be carefully monitored.
- Diagnostic signs: The pharmacological activity of ibuprofen in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
- Corticosteroids: Ibuprofen cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation.
- Aseptic meningitis: Aseptic meningitis with fever and coma has been observed on rare occasions. It is probably more likely in patients with systemic lupus erythematosus and related connective tissue diseases, but it has been reported in patients who do not have an underlying chronic disease.
- Laboratory monitoring: Patients on long-term treatment with NSAIDs should have their CBC and chemistry profile checked periodically.
Common Side Effects
- Gastrointestinal: The most frequent type of adverse reaction is gastrointestinal, and in controlled clinical trials the percentage of patients reporting one or more gastrointestinal complaints ranged from 4% to 16%. Nausea, epigastric pain and heartburn occurred in 3% to 9% of patients, and diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, and bloating and flatulence in more than 1% but less than 3%.
- Other: Dizziness and rash occurred in 3% to 9% of patients. Headache, nervousness, pruritus, tinnitus, decreased appetite, edema and fluid retention occurred in more than 1% but less than 3%.
- Eye and vision: Amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision) occurred in less than 1%, with a probable causal relationship. Conjunctivitis, diplopia, optic neuritis and cataracts occurred in less than 1%, with the causal relationship unknown.
Pregnancy: Use of NSAIDs, including ibuprofen, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. Limit dose and duration of use between about 20 and 30 weeks of gestation, and avoid use at about 30 weeks of gestation and later in pregnancy.
Lactation: It is not known whether ibuprofen is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established, and controlled clinical trials of ibuprofen tablets in children have not been conducted.